Does early detection (by prostate-specific antigen [PSA] testing and digital rectal examination) and treatment of prostate cancer reduce the risk of death from prostate cancer among men aged 45–80 years invited to screening?
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- 1. Barratt AL, Irwig L, Glasziou P, et al. Users’ guides to the medical literature. XVII. How to use guidelines and recommendations about screening. JAMA 1999; 281: 2029-2034.
- 2. Shultz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995; 273: 408-412.
- 3. Cuzick J, Edwards R, Segnan N. Adjusting for non-compliance and contamination in randomized clinical trials. Stat Med 1997; 16: 1017-1029.
- 4. Glasziou P. Meta-analysis adjusting for compliance: the example of screening for breast cancer. J Clin Epidemiol 1992; 45: 1251-1256.
Online responses are no longer available. Please refer to our instructions for authors page for more information.
We would like to thank Professor Les Irwig for comments on earlier drafts of this article.
None identified.